Jamie Harrell is Senior Vice President, Commercialization and Market Development and is responsible for shaping the Company’s commercial and market development strategy. His focus is helping to advance Fate’s lead programs, supporting the paradigm shift of cellular therapies in the outpatient setting and building the foundation for future commercialization. Jamie is an accomplished global commercial leader with more than 25 years of experience in end‑to‑end commercialization, building and scaling biopharmaceutical businesses across rare disease, autoimmune, and specialty therapeutics. He has led the development and execution of commercial strategy for first‑in‑class therapies that reshaped clinical practice, contributed to more than thirty marketed products, seven first-in-class therapies with five major launches. He has launched three block-buster brands that each exceeded annual sales in the U.S. of greater than $1 billion (Lovenox®, Remicade® and Synagis®). Before joining Fate, Jamie worked at Aurina Pharmaceuticals leading the marketing and commercial operations for LUPKYNIS® in Lupus Nephritis. Prior to that, he held roles at Avalo Therapeutics as the Chief Commercial Officer working on pre-market development for six rare disease assets and as the General Manager for Covidien, where he led a 350-person commercial organization. Jamie received his B.S. in Business Administration with an emphasis on Marketing and Economics from Samford University.